Upadacitinib

Autor: Karel, Pavelka, Zoltán, Szekanecz, Nemanja, Damjanov, Branimir, Anić, Matija, Tomšič, Vadim, Mazurov, Marija, Maksimovic, Orsolya, Nagy, Jerzy, Świerkot, Tzvetanka, Petranova, Tiina, Veldi, Asta, Baranauskaitė, Catalin, Codreanu, Daina, Andersone, Roy, Fleischmann

Publikováno v: Drugs in Context

Background In the randomized, phase III, global SELECT-COMPARE study, upadacitinib 15 mg demonstrated efficacy at week 12 versus placebo and adalimumab with methotrexate (MTX) in patients with rheumatoid arthritis and inadequate response to MTX, whic

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::5d36d2db92403b571ec0a321ffc99121
https://pubmed.ncbi.nlm.nih.gov/33123205

Efficacy and Safety of Rivaroxaban Compared With Warfarin Among Elderly Patients With Nonvalvular Atrial Fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF)

Autor: Keith Fox, Konstantin Ramshev, Jacek Kubica, Miguel Urina, Gianfranco Parati, Sotir Marchev, Graeme Hankey, WILLIAM HEDDLE, Claudio Marabotti, Michel GALINIER, Vladimir Zadionchenko, Roman Libis, Fernando Lanas, Malcolm Robert Macleod, Tomas Janota, Markku Kaste, Vadim Mazurov, Larisa Yena, Aleksandr DEMIN

Publikováno v: Circulation. 130:138-146

Background— Nonvalvular atrial fibrillation is common in elderly patients, who face an elevated risk of stroke but difficulty sustaining warfarin treatment. The oral factor Xa inhibitor rivaroxaban was noninferior to warfarin in the Rivaroxaban Onc

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::545541729d7d88f857ecdb78c105121c
https://doi.org/10.1161/circulationaha.113.005008

Administration of monoclonal antibodies to b-lymphocytes (rituximab) in rheumatoid arthritis in Russia

Autor: Nasonov, E. L., Lukina, G. V., Sigidin, Ya A., Bazevich, L. A., Zlobina, T. I., Kamalova, R. G., Knyazeva, L. A., Vadim Mazurov, Menshikova, L. V., Sizikov, A. E., Smirnova, E. A., Fofonova, N. A., Shabalina, T. V., Shkil, L. M., Yudina, N. V., Yakushin, S. S.

Publikováno v: Терапевтический архив, Vol 80, Iss 8, Pp 57-62 (2008)
Scopus-Elsevier

Aim. To assess efficacy and tolerance to anti-B-cell drug rituximab in therapy of rheumatoid arthritis (RA) by the data of RF register of this drug. Material and methods. Rituximab was studied in 42 patients with high RA activity. 37 patients receive

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::754b82755d790f98431648cf310e7ca2
https://ter-arkhiv.ru/0040-3660/article/view/30234

Rivaroxabán versus warfarina en la fibrilación auricular no valvular

Autor: Keith Fox, Scott Berkowitz, Konstantin Ramshev, Jacek Kubica, Miguel Urina, Sotir Marchev, Graeme Hankey, WILLIAM HEDDLE, Claudio Marabotti, Michel GALINIER, Philippe Gabriel STEG, Vladimir Zadionchenko, Fernando Lanas, Juan Mauricio Pardo-Oviedo, Malcolm Robert Macleod, Dorairaj Prabhakaran, Vadim Mazurov, Larisa Yena, Aleksandr DEMIN

Publikováno v: New England Journal of Medicine
New England Journal of Medicine, Massachusetts Medical Society, 2011, 365 (10), pp.883-91. ⟨10.1056/NEJMoa1009638⟩
The New England Journal of Medicine
Repositorio EdocUR-U. Rosario
Universidad del Rosario
instacron:Universidad del Rosario
ResearcherID
BASE-Bielefeld Academic Search Engine

International audience; BACKGROUND: The use of warfarin reduces the rate of ischemic stroke in patients with atrial fibrillation but requires frequent monitoring and dose adjustment. Rivaroxaban, an oral factor Xa inhibitor, may provide more consiste

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a251ed4738fc9d57f063feef4b22b7bf
https://hal.univ-brest.fr/hal-01038111

Tiotropium versus salmeterol for the prevention of exacerbations of COPD

Autor: Oleksii Korzh, Leonardo Fabbri, Frans Van de Werf, António Domingos, Roman Gorenkov, Vadym Vizir, Klaus F. Rabe, Andrzej Bozek, Vladimir Zadionchenko, RICHARD RUSSELL, Andriy Bazylevych, Vadim Mazurov, Maureen Rutten-van Molken

Publikováno v: ResearcherID
Repositorio Abierto de la UdL
Universitad de Lleida
New England Journal of Medicine, 364(12), 1093-1103. Massachussetts Medical Society
Recercat. Dipósit de la Recerca de Catalunya
instname

Background Treatment guidelines recommend the use of inhaled long-acting bronchodilators to alleviate symptoms and reduce the risk of exacerbations in patients with moderate-to-very-severe chronic obstructive pulmonary disease (COPD) but do not speci

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::784282949b0f6ca1073377806860b5bf
https://pubmed.ncbi.nlm.nih.gov/22167844